Solid growth for Japanese Rx market despite March disaster
This article was originally published in Scrip
Executive Summary
The lack of a general biennial price revision this April helped Japan's prescription market grow by 5.3% to ¥2,313.8 billion ($30.2 billion) at official reimbursement prices in the three months to 30 June, with new diabetes therapies providing much of the impetus.